Q1 2025 Financial Performance - Revenue reached $998 million, with a reported growth of +4% and organic growth of +5%[1] - Operating profit was $317 million, representing 31.7% of revenue[1] - Diluted earnings per share (EPS) grew by +5% to $2.96[1] Segment Performance - CAG (Companion Animal Group) revenue totaled $920 million, with reported growth of +3% and organic growth of +4%[1] - Water revenue was $45 million, showing reported growth of +5% and organic growth of +7%[1] - LPD (Livestock, Poultry and Dairy) revenue reached $29 million, with reported growth of +1% and organic growth of +4%[1] - Within CAG Diagnostics Recurring revenue, IDEXX VetLab® Consumables grew by +9% reported and +10% organically, reaching $345 million[1] - Reference Laboratory Dx and Consulting Services revenue was $344 million, with 0% reported growth and +1% organic growth[1] Premium Instrument Placements - Catalyst® placements totaled 1,469 worldwide, with 530 in the U S and 939 internationally[1] - Premium Hematology placements reached 1,597 worldwide, with 441 in the U S and 1,156 internationally[1] - SediVue® Dx placements were 795 worldwide, with 288 in the U S and 507 internationally[1] 2025 Outlook - Revenue is projected to be between $4,095 million and $4,210 million, with reported growth of 5 0% to 8 0% and organic growth of 6 0% to 9 0%[6] - EPS is expected to be between $11 93 and $12 43, with reported growth of 12% to 17%[6] - Capital expenditures are estimated at approximately $160 million[6] U.S. Companion Animal Practice Growth - As of March 31, 2025, U S companion animal practice revenue showed a year-over-year growth of +2 3% per practice[9] - Total visits experienced a year-over-year decline of -2 6% per practice[9] - Clinical visits decreased by -2 3%, while non-wellness visits showed a decline of -2 6%[9]